FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

doi:10.1016/j.pharmthera.2020.107590

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

FGFR4: A promising therapeutic target for breast cancer and other solid tumors.

Pharmacology & therapeutics - 1 Oct 2020

Levine Kevin M, Ding Kai, Chen Lyuqin, Oesterreich Steffi

Abstract excerpt

The fibroblast growth factor receptor (FGFR) signaling pathway has long been known to cancer researchers because of its role in cell survival, proliferation, migration, and angiogenesis. Dysregulation of FGFR signaling is frequently reported in cancer studies, but most of these studies focus on FGFR1-3. However, there is growing evidence implicating an important and unique role of FGFR4 in oncogenesis, tumor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Biomarkers, Tumor
Share to Breast Neoplasms
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Protein Kinase Inhibitors

Share to Receptor, Fibroblast Growth Factor, Type 4

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 32492514
DOI: 10.1016/j.pharmthera.2020.107590
PMCID: PMC7494643

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.